JPMorgan raised the firm’s price target on Elevance Health to $631 from $628 and keeps an Overweight rating on the shares. The firm believes diversified managed care organizations and hospitals remain best positioned within its large cap coverage universe. Within managed care, a more defensive approach is still the best way to play the group over the near-term, the analyst tells investors in a research note. JPMorgan remains more cautious on Medicare Advantage given lack of visibility on 2024 cost trends and uncertainty around 2025 bids.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health price target raised to $585 from $575 at Mizuho
- Elevance Health price target raised to $600 from $580 at Truist
- Elevance Health price target raised to $575 from $574 at RBC Capital
- Elevance Health price target raised to $600 from $557 at Wells Fargo
- Elevance Health price target raised to $605 from $585 at UBS